Revenue
No reported data
Tyra Biosciences, Inc. (TYRA)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $102.9M | $80.1M | $62.5M | $43.0M | $20.6M | $7.2M |
| Operating expenses | $132.8M | $104.2M | $79.9M | $58.9M | $26.3M | $9.3M |
| Operating income | −$132.8M | −$104.2M | −$79.9M | −$58.9M | −$26.3M | −$9.3M |
| EBITDAderived | −$132.2M | −$103.7M | −$79.6M | −$58.6M | −$26.1M | −$9.3M |
| Net income | −$119.9M | −$86.5M | −$69.1M | −$55.3M | −$26.3M | −$9.3M |
| Basic EPSper diluted share | -$2.01 | -$1.51 | -$1.62 | -$1.32 | -$1.91 | -$6.05 |
| Diluted EPSper diluted share | -$2.01 | -$1.51 | -$1.62 | -$1.32 | -$1.91 | -$6.05 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 25, 2026Form 4 | KAPLAN GILLADirector | SellCommon Stock | 14.3K | $36.97 | $528.5K | 28.2K |
| Feb 12, 2026Form 4 · 10b5-1 | Bensen DanielChief Discovery Officer | SellCommon Stock | 5.9K | $33.37 | $195.9K | 147.0K |
| Feb 12, 2026Form 4 · 10b5-1 | Bensen DanielChief Discovery Officer | SellCommon Stock | 2.1K | $31.50 | $67.0K | 152.9K |
| Jan 12, 2026Form 4 · 10b5-1 | Bensen DanielChief Discovery Officer | SellCommon Stock | 1.0K | $29.08 | $29.6K | 155.0K |
| Jan 12, 2026Form 4 · 10b5-1 | Bensen DanielChief Discovery Officer | SellCommon Stock | 7.0K | $28.44 | $198.6K | 156.0K |